Intuitive Surgical (ISRG) Projected to Post Earnings on Tuesday

Intuitive Surgical (NASDAQ:ISRG) will likely be issuing its quarterly earnings data after the market closes on Tuesday, April 22nd. Analysts expect the company to announce earnings of $1.71 per share and revenue of $2.19 billion for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Intuitive Surgical Trading Up 0.3 %

Shares of ISRG stock opened at $482.74 on Monday. The stock has a 50 day simple moving average of $522.23 and a 200 day simple moving average of $532.71. The stock has a market cap of $171.94 billion, a P/E ratio of 75.31, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. Intuitive Surgical has a 1 year low of $364.31 and a 1 year high of $616.00.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Truist Financial reduced their price target on shares of Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. Bernstein Bank upped their target price on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. BTIG Research set a $560.00 price target on Intuitive Surgical and gave the stock a “buy” rating in a report on Monday, April 14th. Royal Bank of Canada raised their price objective on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Finally, Citigroup raised their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $611.81.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 11,545 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the completion of the sale, the executive vice president now owns 5,224 shares of the company’s stock, valued at $2,607,925.28. This trade represents a 68.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock valued at $17,691,621 in the last quarter. Insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

An institutional investor recently raised its position in Intuitive Surgical stock. Brighton Jones LLC increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 24.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,672 shares of the medical equipment provider’s stock after purchasing an additional 731 shares during the period. Brighton Jones LLC’s holdings in Intuitive Surgical were worth $1,916,000 as of its most recent SEC filing. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.